Yes dermatology. Investor long term, but ignored it while it was in the doldrums. Started watching it as it rose to 10. I'm now in the black, but I'd have to say it has certainly taken way too long. Fortunately I only have 4500 shares. I really wasn't expecting it to get to the black, held off selling in order to apply the loss to capital gains in Integro, which should happen in a year or two.
As a physician, I can tell you that you are wrong. Pharm reps can't discuss off label use, but physicians that ask about it are directed to a research specialist in the company, who then sends info including article reprints.
I have advised against this stock on several fora, even with approval, they must get a CPT code- not easy. I know, I serve on several committees for the American Academy of Dermatology. Furthermore, there are several devices on the near horizon which appear far superior. One derm's opinion...
Unlikely that the study design will be placebo controlled. This situation typically calls for the control to be another drug approved for the condition.
I have a few shares, tried to add at .82, still considering.
I only look here occasionally, rarely post, been called a basher the last time.
I am not familiar with the regulatory process in Italy, nor the attendant costs thereof. My speculation is that the costs and regulatory hurdles will likely be greater in the US. Revenue≠profit.
I'm merely a dermatologist with the patience, facility, patient population, and most importantly, the staff necessary to be part of multi-center drug trials. I don't know if that qualifies me as being in the industry, but to answer your question from a personal perspective, the fact that there are multiple potential avenues for success with INSM is what makes it attractive to me as an investor.
A lot of this is "boilerplate". I participate in a number of such studies. Companies don't reinvent the wheel each time. The most important things are IRB approval, appropriate investigators (understanding the imperative to report SAE's within 24 hours), and the consent process. I am an investor, but there are substantial costs involved in such trials. Investigators must be paid, as there is substantial record keeping involved, records must be retained for 5 years after the trial ends, and we are subject to FDA inspection at any time, which is why there is on site monitoring by the sponsoring company. My last post led to an accusation that I am a basher, I am not, I hope this goes to $20 as I will be able to retire on schedule.
I'm not short, just a guy who got greedy a few years ago, and bought 30K shares at an average of 1.99. In retrospect, a dumb move. I hope I'm wrong, and it soars, as I still own 25K shares. In fact, I've only shorted once - rode FNM down from 25.75 to 10 recently. As I wrote, I hope I'm wrong, I'll gladly take an erasure of some of my loss on this one.
Got out of INSM when they lost the suit. That surprised me. Doing great as an early adopter of SmartLipo, just upgraded to the MPX. I keep an eye on CYNO, but haven't bought yet. Underwater in MRX, expect to sell on the news of Reloxin's FDA approval. Could be a good one for a quick play. Chickened out, and covered my short position in FNM Friday - rode it down from $25.75. Should have held on I suppose. Don't be greedy, I told myself. Looking at shorting COF. Economy hasn't affected liposuction, filler/Botox injections yet in my practice.
I quit looking at this message board when yahoo changed the format, what was that? 2 yrs ago? Same old posters: trok, drive (I thought it was nineninesix, you changed?), cricket, jls, w_bth. Where's Isaak? I still have a few K shares, unwilling to admit such a good story/buyout prospect will continue to be ignored. Delusional, maybe. Any new residents in the asylum?
No soul? hahahahaha Each year I give away more than I made when I covered Friday. Don't be a FOOL, shorting is just another way to make money. Next short - COF. Join me if you want to recoup some money.
I just checked, I sold at $25.75 (sorry for the inaccuracy) on 6/12 because it looked as though the leverage was great enough that even minor increase in default rate would create fear of insolvency. I didn't consult LEH. Lucky guess, maybe. I had thought to cover around $15. but it just kept going. Maybe it will continue to drop, but I'm happy with my profit at this point.
I shorted this stock at Scottrade a few weeks ago when it was at $25.85. No problem whatsoever. Covered today, too. $weet